Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Alkylating agent
DRUG CLASS:
Alkylating agent
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
cyclophosphamide (66)
trabectedin (24)
STAR-001 (16)
lomustine (15)
carmustine (14)
lurbinectedin (11)
melphalan (9)
chlorambucil (7)
melphalan flufenamide (7)
temozolomide gel (7)
procarbazine hydrochloride (4)
OBI-3424 (4)
D19466 (4)
mitomycin (3)
thiotepa (3)
bendamustine RTD (2)
LP-284 (2)
fotemustine (2)
busulfan (2)
VAL-083 (2)
ACHM-025 (1)
FGX15-147-based ADC (1)
treosulfan (1)
IMGS-101 (1)
bendamustine rapid infusion (0)
ranimustine (0)
carmustine implant (0)
TL-118 (0)
altretamine (0)
mechlorethamine (0)
PR104 (0)
pegylated liposomal mitomycin-c prodrug (0)
QBS72S (0)
mechlorethamine gel (0)
EX-204 (0)
captisol-enabled melphalan (0)
cyclophosphamide intravenous (0)
D 19575 (0)
CB1954 (0)
cyclophosphamide (66)
trabectedin (24)
STAR-001 (16)
lomustine (15)
carmustine (14)
lurbinectedin (11)
melphalan (9)
chlorambucil (7)
melphalan flufenamide (7)
temozolomide gel (7)
procarbazine hydrochloride (4)
OBI-3424 (4)
D19466 (4)
mitomycin (3)
thiotepa (3)
bendamustine RTD (2)
LP-284 (2)
fotemustine (2)
busulfan (2)
VAL-083 (2)
ACHM-025 (1)
FGX15-147-based ADC (1)
treosulfan (1)
IMGS-101 (1)
bendamustine rapid infusion (0)
ranimustine (0)
carmustine implant (0)
TL-118 (0)
altretamine (0)
mechlorethamine (0)
PR104 (0)
pegylated liposomal mitomycin-c prodrug (0)
QBS72S (0)
mechlorethamine gel (0)
EX-204 (0)
captisol-enabled melphalan (0)
cyclophosphamide intravenous (0)
D 19575 (0)
CB1954 (0)
›
Associations
(199)
News
Trials
Search handles
@AaronGoodman33
@BijoyTelivala
@DrOlaLandgren
@FrancescoMaura4
@JoshuaRichterMD
@Myeloma_Doc
@PestanaRC
@ShannonWestin
@StephenVLiu
@Transplant_Doc
@VivekSubbiah
@bdermanmd
@esinghimd
@herbloong
@jgong15
@majorajay
@smbenlazar
@szusmani
Search handles
@AaronGoodman33
@BijoyTelivala
@DrOlaLandgren
@FrancescoMaura4
@JoshuaRichterMD
@Myeloma_Doc
@PestanaRC
@ShannonWestin
@StephenVLiu
@Transplant_Doc
@VivekSubbiah
@bdermanmd
@esinghimd
@herbloong
@jgong15
@majorajay
@smbenlazar
@szusmani
Filter by
Latest
9ms
True but you expect the lymphoma to respond atleast a little to Adria + Cytoxan and the Dex they get with chemo (@BijoyTelivala)
9 months ago
cyclophosphamide
9ms
📢Revisiting the role of alkylating agents in #MultipleMyeloma: Up-to-date evidence & future perspectives Read➡️https://t.co/zKpCUiWJnt #cancereducation @JoshuaRichterMD @theMMRF @MyelomaTeacher @IMFmyeloma @myeloma_doc_com @WCMMyelomaCtr @multiplemyelom1 @HealthtreeMM @acweyand (@bloodmeded)
9 months ago
9ms
No conference on lung cancer is complete without a good pun from the one & only @DrSteveMartin 😂 Excellent summary of the activity of lurbinectedin in the 2L setting for patients with SCLC #DAVAHawaiiLung #lcsm (@esinghimd)
9 months ago
Clinical
|
Zepzelca (lurbinectedin)
9ms
"So when you're snorkeling with all the fish and wondering why they don't get SCLC, maybe it's because of the sea squirt!" - @DrSteveMartin delivers a witty and Hawaii-appropriate lecture on the antitumor activity of lurbinectedin in 2L SCLC #DAVAHawaiiLung https://t.co/mK0i1Ni28E (@KE_Gallaway)
9 months ago
Zepzelca (lurbinectedin)
9ms
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study @CCR_AACR @AACR @OncoAlert https://t.co/13lijTVndA (@VivekSubbiah)
9 months ago
Clinical
|
Zepzelca (lurbinectedin)
9ms
🤔Is there still a place for alkylating agents in modern-day MM management❓ Learn More➡️https://t.co/zKpCUiXhd1 #MYELOMA #cancereducation #MedTwitter @JoshuaRichterMD @theMMRF @MyelomaTeacher @IMFmyeloma @Myeloma_Doc @WCMMyelomaCtr @multiplemyelom1 @HealthtreeMM @MM_Hub (@bloodmeded)
9 months ago
9ms
https://t.co/bLP9SKNle9 #zepzelca #pharmamar @PhrmMar @VivekSubbiah "Results and biomarker analyses from these studies and others are eagerly awaited to clearly define the role of #lurbinectedin for the management of neuroendocrine neoplasms beyond #SCLC." @OncoscienceJrnl (@pistoto2017)
9 months ago
Zepzelca (lurbinectedin)
10ms
@PazAresLab @StephenVLiu @VivekSubbiah @dr_ponce_aix @NarjustFlorezMD @teekayowo @LaurenByersMD @Tony_Calles @sands_jacob @Latinamd May be fyi 👇🏻#sclc #lurbinectedin (@pistoto2017)
10 months ago
Zepzelca (lurbinectedin)
10ms
Moving to secondary CNS lymphoma, consolidative thiotepa ASCT does improve outcomes. CAR-T in SCNSL with 46% ORR. Great algorithm by Dr. @CwynKate on SCNSL management. #17ICML #lymsm (@majorajay)
10 months ago
thiotepa
10ms
Recent Advances in SCLC Treatment - 2022 Program: LCVL https://t.co/IrEotuY3xF via @YouTube In this video, Dr. @StephenVLiu discusses recent drug advances for SCLC, including Lurbinectedin, Tarlatamab, and the antibody-drug conjugate DS-7300. (@cancerGRACE)
10 months ago
Video
|
Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • tarlatamab (AMG 757)
10ms
Congratulations on your latest review on @CHematology! It is great to see that alkylating agents are still considered to play a key role in the dynamic field of myeloma therapy. (@AnnaL7472838445)
10 months ago
Review
10ms
Trabectedin + Nivolumab promising in L-sarcomas. Clearly, though, we need to select by more than initial letter of the histologic subtype to know who will benefit. #sarcoma #ASCO23 (@PestanaRC)
10 months ago
Opdivo (nivolumab) • Yondelis (trabectedin)
10ms
@PBarataMD highlights: 1) PhI-II dual-PSMA targeting with alpha mAb Ac-J591 + Lu-PSMA (n=18) mCRPC after >1 ARPI 2/6 DLTs at 40 KBq/Kg Ac-J591 w/50% w/PSA50 decline, 2) PhI CAR-T w/PSCA marker in #mCRPC >1 ARPI (n=14) no DLTs w/100M + cytoxan 300mg/m2 feasible #ASCO23 @OncoAlert (@jgong15)
10 months ago
IO biomarker
|
PSCA (Prostate Stem Cell Antigen 2)
|
cyclophosphamide
10ms
🔬 New study explores DNA direct reversal repair (DRR) & alkylating agent drug resistance in cancer treatment. @mrsprostate @KDRichardson924 @nnavai @BreastCancerNow @DanaFarber 👉https://t.co/xZN2xk0iqL #DNARepair #DrugResistance #CancerResearch (@cdrjournal)
10 months ago
10ms
Feels like a good place to drop our new article “Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials” - https://t.co/o5ZHZh0oxe (@AkivaDiamond)
10 months ago
Clinical
|
Leukeran (chlorambucil)
10ms
Revisiting the Role of Alkylating Agents in Multiple Myeloma: @mdbrunocosta @tarekmd91 #mmsm @TischCancer @MountSinaiNYC https://t.co/JMWQhV2fhl (@JoshuaRichterMD)
10 months ago
10ms
6 años de Mieloma Múltiple, una historia donde Melfalan ha sido el protagonista. Some Multiple Myeloma are good citizens. 6 years of suffering multiple myeloma, a story where oral melphalan has been the protagonist. @mvmateos #MultipleMyeloma #hope (@miguelherrerasl)
10 months ago
melphalan
10ms
Will be interesting to find dissect this a bit further, but these are the topline results. #MDM2 #Milademetan #Trabectedin #DDLPS #drugdevelopment #noteasypath #sarcoma (@herbloong)
10 months ago
Yondelis (trabectedin) • milademetan (RAIN-32)
11ms
i will never forget the CLL approvals that had chlorambucil as a control arm. I bet there are now oncologists practicing that ever even gave that to a CLL patient. think I last prscribed it around 2003. but there are category 1 treatments that were based on beating that control (@abbottmd)
11 months ago
Clinical
|
Leukeran (chlorambucil)
11ms
European Commission grants #OrphanDrug designation to #PharmaMars #Lurbinectedin for the treatment of #SoftTissueSarcoma $PHM https://t.co/jZgw2c3SiW (@1stOncology)
11 months ago
European regulatory • Orphan drug
|
Zepzelca (lurbinectedin)
11ms
God speed. Too late for me, but the only effect of myeloma I still feel today is the neuropathy that started with the melphalan and my ASCT. (@arcticllama)
11 months ago
melphalan
11ms
Masterfully laying down the key issues relevant to replacing high dose melphalan with CART in the front-line setting @SagarLonialMD #COMy2023 #mmsm (@szusmani)
11 months ago
melphalan
11ms
Abstracts of #lurbinectedin in the next ASCO conference #ASCO2023 #zepzelca #pharmamar #sclc #leiomyosarcoma (@pistoto2017)
11 months ago
Zepzelca (lurbinectedin)
11ms
"Lurbinectedin is not only safe and effective but is also cost-effective in the care of patients with relapsed #SCLC," said @AparGanti MD, MS. #ISPOR23 | @ISPORorg @unmc https://t.co/pEOyH3TzZO (@TargetedOnc)
11 months ago
Clinical • HEOR • Cost effectiveness
|
Zepzelca (lurbinectedin)
11ms
Dr. @NouraChoudhury with a great overview of #SCLC at #OncLiveSOSS. Chemo-IO is our accepted 1L SOC. Ongoing investigation in lurbinectedin maintenance, salvage tarlatamab, and B7H3 ADCs like I-DxD offer reason for optimism. #LCSM (@StephenVLiu)
11 months ago
Clinical
|
CD276 (CD276 Molecule)
|
Zepzelca (lurbinectedin) • tarlatamab (AMG 757)
12ms
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma https://t.co/lwjW57Z64j #mmsm (@smbenlazar)
12 months ago
Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
melphalan
1year
Post-transplant cyclophosphamide reduced the risk of severe GVHD in patients with deleterious germline DDX41-associated myeloid neoplasms who received HSCT, according to research by @CanerSaygin of @UChicago, and colleagues. https://t.co/17DlZa1gVe (@Blood_Cancers)
1 year ago
Clinical • Post-transplantation
|
DDX41 (DEAD-Box Helicase 41)
|
cyclophosphamide
1year
Thanks @Rfonsi1 for the opportunity to comment on the recent paper entitled “High-Dose Melphalan Treatment Increases Mutational Burden at Relapse in Patients With Multiple Myeloma” | PracticeUpdate #mmsm #wgs https://t.co/5xkFQRT6da (@FrancescoMaura4)
1 year ago
Clinical • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
melphalan
1year
High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. Increased mutational load also increases clonal complexity but does not affect the outcome later #mmsm #bmtsm https://t.co/bpXJVjtutg (@Transplant_Doc)
1 year ago
Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
melphalan
1year
3 recent papers in @BloodJournal and @BloodAdvances showed the effect of high-dose melphalan in TP53 mutated progenitors and myeloma cells #mmsm Great papers answer and generate many questions. How many patients have TP53 mutated (sub)clonal hematopoiesis? Should it be screened? (@BrunoPaiva_UNAV)
1 year ago
Clinical
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
melphalan
1year
🧬🎯Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study 1/4 @myESMO @ESMO_Open @oncoalert #bcsm https://t.co/BpbrRNURx1 (@VivekSubbiah)
1 year ago
Clinical • Pan tumor • Metastases
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study @ESMO_Open @myESMO https://t.co/V9nZ5SSKoi (@VivekSubbiah)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
⭐️Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study #BCSM @myESMO @ESMO_Open @OncoAlert @weoncologists Open access link: https://t.co/O2RjbqO1cG (@VivekSubbiah)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
The current efficacy results in patients with germline BRCA-mutated metastatic breast cancer show lurbinectedin as an active and safe agent in this population, especially in patients with BRCA2 mutations. These results are in line with findings in a previous phase II trial. (@pistoto2017)
over 1 year ago
Clinical • P2 data
|
BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA mutation
|
Zepzelca (lurbinectedin)
over1year
#Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline #BRCA1/2 metastatic breast cancer #mBC: results from a #phaseII basket study @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/dC0PuxFXpY (@ESMO_Open)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
Not sure that MTX makes sense here given it doesn’t have activity against myeloma. IT thiotepa +/- RT for me. Cd20+ that would allow for it rituximab? The eber makes me wonder. Good luck! (@bdermanmd)
over 1 year ago
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • thiotepa
over1year
Is it plasmablastic lymphoma? typically CD20 neg, would have used Len/pom initially due to CNS activity. Now i would do cranial XRT then matrix followed by carmustine/thiotepa based auto (@doctorimran77)
over 1 year ago
CD20 (Membrane Spanning 4-Domains A1)
|
carmustine • thiotepa
over1year
In preclinical models it was shown that lurbinectedin is effective in suppressing the activity of the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus and delayed tumor growth in mice bearing Ewing sarcoma xenografts. https://t.co/9GuHlsaZvv (@VivekSubbiah)
over 1 year ago
Preclinical
|
EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
Zepzelca (lurbinectedin)
over1year
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study https://t.co/M3FOwYB9cH (@VivekSubbiah)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
⭐️Open access article now available online 👉Lurbinectedin -Selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic #breastcancer: results from a phase II basket study @OncoAlert @myESMO @ESMO_Open #ESMO22 https://t.co/C9rwbE24rn (@VivekSubbiah)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
⭐️Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study #bcsm @OncoAlert @weoncologists @myESMO @ESMO_Open https://t.co/YzOc52lMSa (@VivekSubbiah)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
over1year
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study https://t.co/xH0pul149I (@VivekSubbiah)
over 1 year ago
Clinical • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Zepzelca (lurbinectedin)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login